The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children
NCT ID: NCT03384719
Last Updated: 2021-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
129 participants
INTERVENTIONAL
2018-01-18
2018-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Milk Protein and Vitamin D on Children's Growth and Health
NCT03956732
The Effect of Whey and Casein on IGFs in Prepubertal Boys
NCT00378820
Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure
NCT01133964
Effect of Energy- and Protein-rich Foods on Physiological Functions and Quality of Life in Undernourished Patients
NCT01240031
Increased Focus on Protein Intake Among Geriatric Patients
NCT03075189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The PROGRO study is a 3-arm randomized, controlled trial. The effect of consuming 35 g pure milk protein/day is compared to intake of 35 g milk and rapeseed protein/day (ratio 30:70 and 54:46, respectively) in 7-8 year old healthy Danish children. The intervention period is 4 weeks and measurements and blood sampling are performed at baseline, week 1 and week 4. A 3-day weighed dietary intake is recorded before each visit. The primary outcome is Insulin-like growth factor-1 (IGF-1).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
35 g protein (30% milk + 70% rapeseed)
35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
35 g protein (30% milk + 70% rapeseed)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
35 g protein (54% milk + 46% rapeseed)
35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
35 g protein (54% milk + 46% rapeseed)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
35 g protein (100% milk)
35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
35 g protein (100% milk)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
35 g protein (30% milk + 70% rapeseed)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
35 g protein (54% milk + 46% rapeseed)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
35 g protein (100% milk)
The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.
Protein powder ingredients (all are food quality):
* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy\*
* The child is willing to consume protein powder twice a day for 4 weeks
* The child is not a picky eater and so does not mind trying new foods and flavours
* The child speaks Danish in order to understand the study procedures
* The parents read and speak Danish in order to be properly informed about the study procedures
* Written informed consent has been obtained
* The principal investigator, who is blinded to study treatment, will perform a case-by-case medical evaluation of children with any signs of being unhealthy or having any illness or taking medication at the time of admission. If the conditions are considered to potentially affect protein metabolism or growth, the children will not be included. If a child is acutely ill at the scheduled time of study start, the child cannot be included. But the child may be included later when the acute illness has resolved
Exclusion Criteria
* Known or suspected allergy, sensitization or intolerance to milk (protein or lactose), rapeseed or mustard
* Any acute illness\*
* Chronic illness or disease that may affect protein metabolism or growth\*
* Chronic intake of medicine that may affect protein metabolism or growth\*
* Concomitant participation in other studies involving dietary supplements or blood sampling
* Living in a household with another participating child
* The principal investigator, who is blinded to study treatment, will perform a case-by-case medical evaluation of children with any signs of being unhealthy or having any illness or taking medication at the time of admission. If the conditions are considered to potentially affect protein metabolism or growth, the children will not be included. If a child is acutely ill at the scheduled time of study start, the child cannot be included. But the child may be included later when the acute illness has resolved
7 Years
8 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arla Foods
INDUSTRY
University of Aarhus
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Mølgaard
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Mølgaard, professor
Role: PRINCIPAL_INVESTIGATOR
Department of Nutrition, Exercise and sports, University of Copenhagen
Benedikte Grenov, postdoc
Role: STUDY_CHAIR
Department of Nutrition, Exercise and sports, University of Copenhagen
Anni Larnkjær, PhD
Role: STUDY_CHAIR
Department of Nutrition, Exercise and sports, University of Copenhagen
Camilla T. Damsgaard, Associate Professor
Role: STUDY_CHAIR
Department of Nutrition, Exercise and sports, University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nutrition, Exercise and Sports
Copenhagen, Frederiksberg, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grenov B, Larnkjaer A, Ritz C, Michaelsen KF, Damsgaard CT, Molgaard C. The effect of milk and rapeseed protein on growth factors in 7-8 year-old healthy children - A randomized controlled trial. Growth Horm IGF Res. 2021 Oct-Dec;60-61:101418. doi: 10.1016/j.ghir.2021.101418. Epub 2021 Jul 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.